26±14 mg/l in the 4-year period prior the start of the study (1980)(1981)(1982)(1983) to 9±6 mg/l in the period Background. A recent retrospective study has clearly demonstrated a reduction of cases with positive bone 1984-1987 and to 4.9±2.1 mg/l and 5.0±2.0 mg/l respectively thereafter (P<0.0001). aluminium (Al ) staining in the Italian dialysis population, which in general has had a low prevalence of Conclusions. Despite the persistence of oral exposure to Al, responsible for the observed stability of serum bone Al toxicity. In the present study we tried to better address the relative role played, in our study popula-Al levels, a definite reduction of bone Al content has been recorded in our dialysis population, and ARBD tion, by enteral and parenteral exposure to Al in reducing bone accumulation.
concentrations in dialysis fluids, the interval 1980-1983 Introduction (immediately before the start of our study), which could clearly have influenced bone Al content, was
Although obvious reductions of both Al-related toxalso considered.
icity and mean serum Al in dialysis patients have Results. Basal serum Al showed some fluctuations certainly occurred in recent years [1, 2] , the possibility (42.7±34.1; 24.8±21.9 and 38.9±34.9 mg/l respectof a mild accumulation (and possibly toxicity) of Al ively in the three groups, ANOVA P<0.01) but only still exists [3] . For instance, Malluche and Moniervalues of the period 1988-1991 were significantly lower Faugere [4] in a retrospective evaluation of their than those of the period 1984-1987 (P<0.05).
population, have reported an increase in the number Increments after DFO did not differ in the of patients exhibiting positive Al staining (>30% of three periods (136.5±105.7; vs 98.7±91.7 and the trabecular surface), from 34% in 1982-1983 to a 106.1±96.2 mg/l respectively, P=n.s.). Enteral expomean stable prevalence of 50% in the following years, sure to drugs containing Al was comparable (4.1±2.9 up to 1991. As far as the Italian dialysis population is vs 4.0±4.6 and 5.8±7.9 total kg ingested respectively; concerned, a low prevalence of Al-related bone disease P=n.s.), but bone Al was dramatically reduced (from (ARBD) has been generally reported [5, 6 ] . Moreover, 60.7±43.0 to 29.0±24.4 and 31.9±29.9 mg/kg/dw in a recent retrospective evaluation of 1429 bone biopsy respectively; P<0.0001), along with the definite disapsamples, a reduction of cases with positive Al staining pearance of Aluminon-positive cases and Al-related (any extent of positivity) from 35.6% in 1985 to 4.2% bone disease (ARBD) after 1991. Parenteral exposure in 1994 has been reported [7] . The aim of the present through the dialysate dropped from a mean of study was to address this issue more accurately by evaluating the relative role that dialysate and intestinal-
Subjects and methods
a mixture of HNO3 1% v/v plus Triton-X 100, 0.1%. [8] . Bone biopsy specimen were washed clean of marrow, defatWe retrospectively examined the data of 105 patients (56 ted, dried, and ashed in an oven before the assay [9] . Our males, 49 females; aged 51.5±17.1 years) on haemodialysis normal values, respectively for serum and bone, are: treatment for 88.1±47 months, who had been referred to 4.5±2.0 mg/l and 2.4±1.1 mg/kg/dw. During the whole our outpatient unit by several dialysis centres of our regional period of the study the same instrumentation and assay area, for the evaluation of renal osteodystrophy, in the period procedures were employed and the Unit participated in some 1984-1995. They were studied by means of a desferrioxamine External Quality Assurance Programmes ( EEC Programme (DFO) infusion test and a transiliac bone biopsy for bone and Italian QC Programme). Al content and histological diagnosis. The test was performed For histological diagnosis and histochemical studies, bone according to the following schedule: basal blood sampling specimens were handled as previously described [10] . Sections before dialysis; DFO infusion at the dose of 28.5 mg/kg/bw 3-4 mm thick were stained using the Al histochemical staining in the last 30 min of treatment; post-DFO sampling after technique (Aluminon). The histopathological diagnoses were approximately 44 h ( just before the next dialysis). At the performed according to the morphological criteria suggested time of the study, an accurate anamnestic assessment of oral by Malluche and Faugere [11] . Briefly, a general increase in phosphate-chelating therapy was performed. In particular, bone turnover rate was designed as predominant hyperparacommercial types and doses of prescribed drugs were thyroidism, while a decrease in bone turnover rate associated recorded, the real compliance to prescription was firmly with an increase of both osteoid surface and thickness was asked for, and the mean daily and total consumption values regarded as osteomalacia. A local increase in bone turnover in each patient were calculated. Moreover, those patients rate coexisting with focal defective mineralization were the with possible presence of a parenteral exposure other than hallmarks of mixed osteodystrophy, and a reduced bone that related to dialysis ( like parenteral nutrition, i.v. albumin turnover associated with thin osteoid seam, bone cell paucity, etc.) were excluded from the study.
and a decrease in tetracycline uptake was referred as adynTo estimate the entity of Al exposition through dialysis amic bone disease. fluids, we have examined the data collected at the Trace Elements Unit of the Applied Toxicology Laboratory of Rome (Istituto Superiore di Sanità) from 1980 to 1995. A Statistics total of 373 samples of different dialysis fluids, were received from several industries and from the same dialysis centres Statistical evaluation was carried out using currently available statistic software (SPSS). Mean±SD for the different referring patients to our unit. Samples were allotted as follows: 94 concentrates; 50 reinfusates; 158 deionized water, groups were calculated. Differences among groups were obtained by analysis of variance or x2 test. When appropriate, and 71 dialysates.
For the purpose of the present study, patients' data were the Bonferroni's test was applied to verify the differences between groups [12]. subdivided into three period groups: 1984-1987; 1988-1991; 1992-1995. In the case of dialysis fluids, because bone Al content may have been influenced by previous exposure, we also considered the 4-year-interval preceding our study Results (1980) (1981) (1982) (1983) Mean biochemical data in the three groups of patients Assay methods are shown in Table 1 . In the three periods considered, basal serum Al values showed some fluctuations Al was measured by the SPTF-AAS technique, using a (42.7±34.1 vs 24.8±21.9 and 38.9±34.9 mg/l; Perkin Elmer 5100 Zeeman (Norwalk, Conn, USA) equipped P<0.01) but only values of the period 1988-1991 were with a HGA-600 graphite furnace and an AS-60 auto-significantly lower than those of the period 1984-1987 sampler. A calibration curve was constructed by running (see Table 1 ). Al increments after DFO were not different Al standards prepared in normal serum with low significantly different (136.5±105.7 vs 98.7±91.7 and endogenous Al content (<3 mg/l ). The standard addition 106.1±96.2 mg/l; P=n.s.). The mean prescribed daily method was also applied to some samples, to verify the dose of phosphate-chelating agents and the cumulative validity of the calibration procedure. Serum samples were diluted with a mixture of magnesium nitrate 2.5 g/l plus dosage of Al were unchanged (P=n.s.). Bone Al content showed a clear halving of mean In our patients, over the time periods considered, a substantial stability of mean serum Al levels along values (from 60.7±43 to 29.0±24.4 and 31.9±29. 9 with a constant oral intake, were recorded. In the mg/kg/dw; P<0.00001) after 1987. The complete disgeneral dialysis population, the percentage of patients appearance of Aluminon-positive cases in more recent who are prescribed an aluminium-hydroxideyears was also noted. In the three observation periods, containing drug has certainly decreased, but in a the distribution of histopathological diagnoses changed selected population like the one in our study, the mean as follows: adynamic bone disease from 0 to 5.6, to daily dose was substantially unchanged in comparison 8.3% (P=n.s.); osteomalacia from 7.1 to 3.7, to 5.5% with previous periods. Therefore the cumulative dosage (P=n.s.); mixed osteodystrophy from 71.4 to 33.9, to was stable, but may increase as a consequence of the 44.4% (x2=10.3; P<0.006); prevailing hyperparathyimprovement in the patients survival rate. In this roidism from 21.4 to 52.8, to 41.6% ( x2=7.4, P<0.02). respect, bone Al content was markedly reduced. The persistence of a relatively high-dose prescription the manufacturers. Al content in deionized water has of Al hydroxide in our patients, could be explained by always been acceptable (8.1±5.0 vs 4.0±2.0 vs changes in the patients' characteristics. As a matter of 2.2±1.0 and vs 2.0±1.2 mg/l; P<0.0001), but in the fact we have recorded a clear increment of cases with last 10 years is definitely safe. As a result, Al concentra-prevailing pure hyperparathyroidism (from 21.4% to tion in dialysate averaged 26.1±14.0 mg/l in 52.8% and 41.6% respectively; P<0.02), i.e. of cases 1980-1983, decreased to 9.0±6.0 mg/l subsequently, who generally have higher levels of serum PTH and and reached unequivocally safe values following 1988 phosphate [17] and which therefore might require a more aggressive oral phosphate chelation therapy. (4.9±2.1 and 5.0±2.0 mg/l; P<0.0001).
In conclusion, despite the persistence of oral exposure to Al, a definite reduction of bone Al content has occurred in our dialysis population, and ARBD has Discussion completely disappeared. This result can be essentially attributed to the optimal control of Al content in With the aim of reducing Al accumulation in dialysis, dialysis fluids, which is therefore confirmed as a major both parenteral and enteral exposure have been signifactor for Al intoxication. Therefore it seems mandatficantly reduced. However, while dialysate exposure ory that Al concentration in dialysate be kept well may be easily controlled, a certain degree of intestinal below 10 mg/l. If this is accomplished, the only residual absorption is often unavoidable [14] . The epidemic route for accumulation of Al in bone and other tissues appearance of Al-related disease secondary to an acci-would nowadays be the prolonged enteral administradental parenteral exposure through dialysate has also tion of Al(OH ) 3 . been recently described [15] , but is expected to disappear rapidly. On the contrary the relative impact of
